

U.S.S.N. 09/807,558

Filed: July 17, 2001

PETITION FOR RECONSIDERATION OF RESTRICTION REQUIREMENT**Appendix: Claims as Pending**

1. (previously presented) A method of treating weight loss due to underlying disease in a patient the method comprising administering to the patient an effective amount of an agent which reduces sympathetic nervous system activity.
2. (original) A method according to Claim 1 wherein the agent which reduces sympathetic nervous system activity is any one or more of the following: a compound which inhibits the effect of aldosterone such as an aldosterone antagonist; a chymase inhibitor; a cathepsin inhibitor; a β receptor blocker; an imidazoline receptor antagonist; a centrally acting α receptor antagonist; a peripherally acting α receptor antagonist; a ganglion blocking agent; a drug that has an effect on cardiovascular reflexes and thereby reduce SNS activity such as an opiate; scopolamine; endothelin receptor antagonist; a xanthine oxidase inhibitor; and erythropoietin.
3. (previously presented) A method claim 1 of treating weight loss due to underlying disease in a patient the method comprising administering to the patient an effective amount of a compound which inhibits the effect of aldosterone, such as an aldosterone antagonist.
4. (original) A method according to Claim 3 wherein the compound which inhibits the effect of aldosterone is any one of spironolactone, testolactone, RU40555, RU26752, canrenoate, eplerenone, 3-(17 β -hydroxy-3-oxoandrosta-1,4,6,11-tetraen-17 α -yl) propionic acid γ lactone, 3-(9- α -fluoro-17 β -hydroxy-3-oxo-androsta-4-en-17 α -yl) propionic acid γ lactone, dihydro-spirorenone, spirorenone, 15,16-methylene derivatives of spironolactone, mespirenone and SC9420.

45048596_1

ICI 102
078230/00027

U.S.S.N. 09/807,558

Filed: July 17, 2001

PETITION FOR RECONSIDERATION OF RESTRICTION REQUIREMENT

5. (previously presented) A method of claim 1 of treating weight loss due to underlying disease in a patient the method comprising administering to the patient an effective amount of a chymase inhibitor.
6. (original) A method according to Claim 5 wherein the chymase inhibitor is any one of alendronate, aprotinin and tissue inhibitors of matrix metalloproteinases.
7. (previously presented) A method of claim 1 of treating weight loss due to underlying disease in a patient the method comprising administering to the patient an effective amount of a cathepsin inhibitor.
8. (original) A method according to Claim 7 wherein the cathepsin B inhibitor is any one of an epoxysuccinyl peptide such as CA-074 or E64-c, stefin A and cystatin C.
9. (previously presented) A method of claim 1 of treating weight loss due to underlying disease in a patient the method comprising administering to the patient an effective amount of a β receptor blocker.
10. (original) A method according to Claim 9 wherein the β receptor blocker is any one of acebutolol, alprenolol, atenolol, betaxolol, bisoprolol, carteolol, celiprolol, esmolol, labetolol, lavobunolol, metipranolol, metoprolol, nadolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, timolol, nebivolol, carvedilol and bucindolol.
11. (previously presented) A method of claim 1 of treating weight loss due to underlying disease in a patient the method comprising administering to the patient an effective amount of an imidazoline receptor antagonist.

45048596_1

ICI 102
078230/00027

U.S.S.N. 09/807,558

Filed: July 17, 2001

PETITION FOR RECONSIDERATION OF RESTRICTION REQUIREMENT

12. (original) A method according to Claim 11 wherein the imidazoline receptor antagonist is any one of moxonidine, rilmenidine, pentamidine and α -methyl dopa.

13. (previously presented) A method of claim 1 of treating weight loss due to underlying disease in a patient the method comprising administering to the patient an effective amount of an imidazoline receptor antagonist.

14. (original) A method according to Claim 13 wherein the centrally acting α receptor agonist is clonidine.

15. (previously presented) A method of claim 1 of treating weight loss due to underlying disease in a patient the method comprising administering to the patient an effective amount of a peripherally acting α receptor antagonist.

16. (original) A method according to Claim 15 wherein the peripherally acting α receptor antagonist is any one of doxazosin, prazosin, terazosin and ipsapirone.

17. (previously presented) A method of claim 1 of treating weight loss due to underlying disease in a patient the method comprising administering to the patient an effective amount of a ganglion blocking agent.

18. (original) A method according to Claim 17 wherein the ganglion blocking agent is any one of azamethonium, dicolinium, hexamethonium, mecamlamine, pentamethonium, pentolinium, trimetaphan, benzohexonium, hexafluorenium, cypenam, trimethaphan canfosulfonate, tetraethylammonium bromide and synapleg.

45048596_1

ICI 102
078230/00027

U.S.S.N. 09/807,558

Filed: July 17, 2001

PETITION FOR RECONSIDERATION OF RESTRICTION REQUIREMENT

19. (previously presented) A method of claim 1 of treating weight loss due to underlying disease in a patient the method comprising administering to the patient an effective amount of a drug that has an effect on cardiovascular reflexes and thereby reduces SNS activity.

20. (previously presented) A method of claim 1 of treating weight loss due to underlying disease in a patient the method comprising administering to the patient an effective amount of an opiate.

21. (original) A method according to Claim 20 wherein the opiate is any one of dihydrocodeine, morphine, diamorphine and buprenorphine.

22. (previously presented) A method of claim 1 of treating weight loss due to underlying disease in a patient the method comprising administering to the patient an effective amount of scopolamine.

23. (previously presented) A method of claim 1 of treating weight loss due to underlying disease in a patient the method comprising administering to the patient an effective amount of an endothelin receptor antagonist.

24. (original) A method according to Claim 23 wherein the ET-1 receptor antagonist is any one of butenolide, BQ123, BQ-788, A-216546, ABT-627, IRL3461, LU135252, S-0139, T-0201, PD 142,893, PD 164333, RO 61-1790, PD 156,707, SB 209670, IRL 1038 and WS-7338

B.

45048596_1

ICI 102
078230/00027

U.S.S.N. 09/807,558

Filed: July 17, 2001

PETITION FOR RECONSIDERATION OF RESTRICTION REQUIREMENT

25. (previously presented) A method of claim 1 of treating weight loss due to underlying disease in a patient the method comprising administering to the patient an effective amount of a xanthine oxidase inhibitor.

26. (original) A method according to Claim 25 wherein the xanthine oxidase inhibitor is any one of allopurinol, 7,8-dihydroneopterin, 5,6,7,8-tetrahydrobiopterin, leukopterin, xanthopterin, neopterin, biopterin, 4-amino-6-hydroxypyrazolo[3,4-d]pyrimidine (AHPP) and oxypurinol.

27. (previously presented) A method of claim 1 of treating weight loss due to underlying disease in a patient the method comprising administering to the patient an effective amount of erythropoietin.

28. (original) A method of treating weight loss due to underlying disease in a patient the method comprising electrically stimulating the patient's muscles.

29. (previously presented) A method according to claim 1 wherein the underlying disease is any one of AIDS, liver cirrhosis, chronic obstructive pulmonary disease with or without emphysema, chronic renal failure, chronic infections, cancer, heart disease including hypertension and chronic heart failure.

30. (previously presented) A method according to claim 1 wherein the patient has idiopathic cachexia.

31. (previously presented) A method according to claim 1 wherein the underlying disease is chronic heart failure and the patient has cardiac cachexia.

45048596_1

ICI 102
078230/00027

U.S.S.N. 09/807,558

Filed: July 17, 2001

PETITION FOR RECONSIDERATION OF RESTRICTION REQUIREMENT

32. (previously presented) Use of a compound as defined in claim 1 in the manufacture of a medicament for treating weight loss due to underlying disease.

Claims 33-34 (cancelled)

35. (previously presented) A method of treating or preventing weight loss due to the aging process in a patient the method comprising administering to the patient an effective amount of an agent which reduces sympathetic nervous system activity.

36. (previously presented) A method of treating or preventing weight loss due to the aging process in a patient the method comprising administering to the patient an effective amount of a compound which inhibits the effect of aldosterone such as an aldosterone antagonist; a chymase inhibitor; a cathepsin inhibitor; a β receptor blocker; an imidazoline receptor antagonist; a centrally acting α receptor antagonist; a peripherally acting α receptor antagonist; a ganglion blocking agent; a drug that has an effect on cardiovascular reflexes and thereby reduce SNS activity such as an opiate, a digitalis alkaloid, scopolamine; an endothelin receptor antagonist; a xanthine oxidase inhibitor; and erythropoietin.

37. (previously presented) A method of treating or preventing weight loss due to the aging process in a patient the method comprising electrically stimulating the patient's muscles.

38. (original) A method of enhancing exercise performance in a healthy patient the method comprising administering to the individual an effective amount of an agent which reduces sympathetic nervous system activity.

45048596_1

ICI 102
078230/00027

U.S.S.N. 09/807,558

Filed: July 17, 2001

PETITION FOR RECONSIDERATION OF RESTRICTION REQUIREMENT

39. (previously presented) A method of enhancing exercise performance in a healthy individual the method comprising administering the individual an effective amount of a compound which inhibits the effect of aldosterone such as an aldosterone antagonist; a chymase inhibitor; a cathepsin inhibitor; a β receptor blocker; an imidazoline receptor antagonist; a centrally acting α receptor antagonist; a peripherally acting α receptor antagonist; a ganglion blocking agent; a drug that has an effect on cardiovascular reflexes and thereby reduce SNS activity such as an opiate; a digitalis alkaloid; scopolamine; an anabolic growth factor like growth hormone and insulin-like growth factor-I (IGF-I); an endothelin receptor antagonist; a TNF α antagonist; a xanthine oxidase inhibitor; and erythropoietin.

40. (original) A method of enhancing exercise performance in a healthy patient the method comprising electrically stimulating the patient's muscles.

41. (previously presented) A method of preventing weight loss consequent to a cardiovascular disorder in a patient at risk of heart disease the method comprising administering to the patient an effective amount of a compound selected from the group consisting of a compound with an inhibiting effect on aldosterone; a β -receptor blocker; an imidazoline receptor antagonist; a centrally acting α receptor agonist; a peripherally acting α receptor antagonist; and a ganglion blocking agent.

Claims 42-45 (cancelled)

46. (original) A method according to claim 28 wherein the underlying disease is any one of AIDS, liver cirrhosis, chronic obstructive pulmonary disease with or without emphysema,

45048596_1

ICI 102
078230/00027

U.S.S.N. 09/807,558

Filed: July 17, 2001

PETITION FOR RECONSIDERATION OF RESTRICTION REQUIREMENT

chronic renal failure, chronic infections, cancer, heart disease including hypertension and chronic heart failure.

47. (original) A method according to claim 28 wherein the patient has idiopathic cachexia.

45048596_1

ICI 102
078230/00027